AZN

Prezzo AstraZeneca

Closed
AZN
$182,85
+$0,33(+0,18%)

*Data last updated: 2026-05-10 11:08 (UTC+8)

As of 2026-05-10 11:08, AstraZeneca (AZN) is priced at $182,85, with a total market cap of $283,46B, a P/E ratio of 26,52, and a dividend yield of 1,77%. Today, the stock price fluctuated between $181,60 and $183,47. The current price is 0,68% above the day's low and 0,33% below the day's high, with a trading volume of 1,18M. Over the past 52 weeks, AZN has traded between $68,61 to $212,72, and the current price is -14,04% away from the 52-week high.

AZN Key Stats

Yesterday's Close$182,52
Market Cap$283,46B
Volume1,18M
P/E Ratio26,52
Dividend Yield (TTM)1,77%
Dividend Amount$2,17
Diluted EPS (TTM)6,74
Net Income (FY)$10,25B
Revenue (FY)$58,73B
Earnings Date2026-07-27
EPS Estimate2,49
Revenue Estimate$15,44B
Shares Outstanding1,55B
Beta (1Y)0.223
Ex-Dividend Date2026-02-20
Dividend Payment Date2026-03-23

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOPascal Claude Roland Soriot
HeadquartersCambridge,None,GB
Employees (FY)2,02K
Average Revenue (1Y)$29,03M
Net Income per Employee$5,06M

AstraZeneca (AZN) FAQ

What's the stock price of AstraZeneca (AZN) today?

x
AstraZeneca (AZN) is currently trading at $182,85, with a 24h change of +0,18%. The 52-week trading range is $68,61–$212,72.

What are the 52-week high and low prices for AstraZeneca (AZN)?

x

What is the price-to-earnings (P/E) ratio of AstraZeneca (AZN)? What does it indicate?

x

What is the market cap of AstraZeneca (AZN)?

x

What is the most recent quarterly earnings per share (EPS) for AstraZeneca (AZN)?

x

Should you buy or sell AstraZeneca (AZN) now?

x

What factors can affect the stock price of AstraZeneca (AZN)?

x

How to buy AstraZeneca (AZN) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

AstraZeneca (AZN) Latest News

2025-03-20 09:53Exclusive Offer for Gate.io - Claim Your Share of Million Dollar Trading Benefits!P2P Event Overview The exclusive trading event for Gate.io CIS users has started. During the event, both new and existing users can complete deposit and trading tasks to earn up to 30 USDT rewards. **Event Dates : March 17, 2025 - April 25, 2025** **Eligible Currencies** : RUB, UAH, KZT, UZS, BYN, AZN, AMD **Event 1: New User Registration Bonus ** During the event, new users who register, complete KYC verification, and meet the following tasks can receive corresponding rewards: * Deposit ≥ 30 USDT: Get a 2 USDT Futures Bonus * Deposit ≥ 100 USDT: Get an 8 USDT Futures Bonus * Deposit ≥ 300 USDT: Get a 25 USDT Futures Bonus **Event 2: Existing User Trading Contest ** During the event, deposit and complete at least one trade to receive corresponding trading fee rebate vouchers: * Deposit ≥ 200 USDT: Get a 3 USDT trading fee rebate voucher * Deposit ≥ 500 USDT: Get a 10 USDT trading fee rebate voucher * Deposit ≥ 1000 USDT: Get a 30 USDT trading fee rebate voucher <div style="text-align: center;"><a data-type="gate-activity" rel="" href="https://www.gate.io/campaigns/617" target="_blank" style="text-decoration: none !important;display: inline-block;"><div class="gateactivity-btn-style" style="width: 240px;height: 40px;box-sizing: border-box;padding: unset;border-radius: 99px;display: inline-flex;align-items: center;justify-content: center;background: #3377FF;cursor: pointer;"><strong><span style="color:#fff; text-decoration: none;">Sign up now</span></strong></div></a></div> **Terms and Conditions** : * This event is available to users in CIS regions, including **RUB, UAH, KZT, UZS, BYN, AZN, AMD.** * Users must **click there to register for the event** to be eligible for rewards. * Trading fee rebate vouchers must be manually activated and can only be activated one at a time. Vouchers expire after the designated time, and after expiration, any remaining balance of the voucher will become void. <a href="https://www.gate.io/help/guide/reward_center/38086/trading-fee-rebate-voucher-introduction" target="_blank">Learn more about Trading Fee Rebate Voucher.</a> * Futures bonuses should be claimed and used for trading within the validity period, and will become invalid after the expiration date. Learn more about <a href="https://www.gate.io/help/futures/bonusvoucher/39028/futures-bonus" target="_blank">Futures Bonus </a>. * Futures trading carries risks; Gate.io is not responsible for any losses incurred using trading fee rebate voucher or engaging in futures trading. * As per our our Users Agreement, this service is unavailable to users in the UK and other restricted locations. * Users who fail to meet the requirements may forfeit their eligibility for rewards. All users must strictly comply with Gate Users Agreement. * Gate.io reserves the right to disqualify any participants engaged in dishonest or abusive activities during the event, including bulk account registrations to obtain additional bonuses and any other activities related to illegal, fraudulent, or harmful purposes. * Gate.io reserves the right to modify the terms of this event without prior notice to users. If you have any questions, please contact your P2P manager via @Gatep2p_bot. Join our Telegram channel: https://t.me/P2P_GateCommunity<sp> **Gateway to Crypto** Trade over 3,700 cryptocurrencies safely, quickly, and easily on Gate.io • Visit our <a href="https://www.gate.io/" target="_blank">Official Website</a> • Download <a href="https://www.gate.io/mobileapp" target="_blank">Gate.io App</a> / <a href="https://www.gate.io/mobileapp" target="_blank">Web</a> now • Follow us on Gate.io <a href="https://x.com/gate_io" rel="nofollow noopener noreferrer" target="_blank">X (Twitter)</a> to get more bonuses • Join our <a href="https://t.me/gateio_en" rel="nofollow noopener noreferrer" target="_blank">Telegram</a> to discuss hot topics • Join our <a href="https://www.gate.io/community" target="_blank">Global Community</a> to get more updates • We provide <a href="https://www.gate.io/proof-of-reserves" target="_blank">100% proof of reserves</a> • <a href="https://www.gate.io/signup" target="_blank">Sign up</a> to enjoy max. $10,000 in rewards exclusively for new users • Get 40% commission from <a href="https://www.gate.io/referral" target="_blank">referrals</a> Gate.io Team March 17, 2025</sp>

Hot Posts su AstraZeneca (AZN)

SelfRugger

SelfRugger

05-07 14:27
This is a paid press release. Contact the press release distributor directly with any inquiries. Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Market Research Report 2026: Soliris and Ultomiris from AstraZeneca and Piasky Have Set the Stage for Next Generation Biosuperiors ============================================================================================================================================================================================== Research and Markets Fri, February 20, 2026 at 12:51 AM GMT+9 3 min read In this article: AZN -0.76% Company Logo _Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, and NMOSD. Emerging modalities target tailored therapeutic impacts for C5-related inflammatory and autoimmune conditions._ Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ** ResearchAndMarkets.com's** offering. This competitive intelligence report about C5 Inhibitors & C5 Receptor Antagonists provides an up-to-date competitor evaluation in the field of emerging therapy candidates in research and development targeting the complement C5 receptor or its ligand C5. The report lists active C5(R) targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of C5 inhibitors & C5 receptor antagonists by drug modality (mainly recombinant antibodies, but also proteins, peptides, RNA and small molecules). Complement component C5 is a pro-inflammatory protein that is part of the classical complement pathway. It plays a crucial role in the activation of C3 and C5, contributing to the inflammatory response associated with conditions like age-related macular degeneration (AMD). In the terminal pathway distal to C3, C5 is the critical component. C5 has some structural similarities to C3: C5 contains macroglobulin domains (MG1-MG8), the CUB domain, the C5d domain (structurally homologous to the TED of C3), the C5a domain (also called anaphylatoxin) and an extended linker region. Native human C5 is a naturally glycosylated (1.6%) polypeptide containing two disulfide-linked chains. C5 is essential for formation of the membrane attack complex (MAC) and is activated by all three pathways of complement activation. Eculizumab (Soliris) is a monoclonal antibody that binds C5 and blocks its proteolytic activation. Eculizumab was approved in 2007 for paroxysmal nocturnal hemoglobinuria (PNH), becoming the first complement inhibitor available to patients. With annual sales of more than US$ 6.53 bln in 2024, first and second generation C5 inhibitor antibodies Soliris and Ultomiris from AstraZeneca (acquired Alexion Pharmaceuticals) and Piasky have set the stage for next generation biosuperiors as well as biosimilars of a commercially successful and clinically effective treatment of complement C5 mediated diseases. New treatment modalities in development aim at improving the mode and frequency of administration as well as the scope of indications. Complement C5-mediated diseases are a group of disorders where the C5 protein of the complement system is implicated in tissue damage, autoimmune processes, and inflammation, including PNH, Atypical Hemolytic Uremic Syndrome (aHUS), Sickle Cell Disease (SCD), Myasthenia Gravis (MG), and Neuromyelitis Optica Spectrum Disorder (NMOSD). These conditions can involve the formation of the Membrane Attack Complex (MAC) or the release of anaphylatoxins like C5a, leading to symptoms such as anemia, blood clots, and kidney damage. For more information about this report visit Story Continues **About ResearchAndMarkets.com** ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0
GateUser-a5fa8bd0

GateUser-a5fa8bd0

2025-12-30 14:00
**Summary** This report provides the real-time exchange rate between the Azerbaijani Manat (AZN) and the Russian Ruble (RUB), helping traders quickly grasp market dynamics and identify potential trading opportunities. ## **Definition** The Azerbaijani Manat (AZN) is the official currency of Azerbaijan, while the Russian Ruble (RUB) is the primary fiat currency of Russia. The exchange rate between them reflects regional economic dynamics and currency market sentiment between these two neighboring economies. ## **Today's Price** - **1 AZN = 45.6 RUB** - **24h High:** 46.2775 RUB - **24h Low:** 45.7259 RUB ## **Market Analysis** Recent AZN/RUB price movements reflect the pair's interaction with key technical levels and moving average indicators. - **Technical levels:** The 50-day moving average stands at 45.6271, suggesting a **Sell signal**. Key support and resistance levels should be identified through analysis of historical price levels and swing highs and lows on the price chart - **Risk note:** Traders should monitor potential price reversals at identified support and resistance zones, as these levels are crucial for determining where the price of the asset is likely to experience reversals - **Trading opportunities:** Focus on identifying support and resistance levels using technical analysis tools such as trendlines, moving averages, and Fibonacci retracements to gain valuable insights into market trends and potential price reversals ## **Conclusion** Continue to monitor the AZN/RUB pair closely, applying technical analysis methods to identify key support and resistance levels. By understanding market structure and price action, traders can develop more informed strategies for this currency pair.
0
0
0
0
ser_ngmi

ser_ngmi

01-12 17:32
**WMT Ascends to Elite Index Club** Nasdaq has confirmed a significant index reshuffle set to reshape its benchmark holdings. Walmart Inc. (WMT) is stepping in to join the Nasdaq-100 Index (NDX), alongside the Nasdaq-100 Equal Weighted Index (NDXE) and the Nasdaq-100 Ex-Tech Sector Index (NDXX) as of January 20, 2026. The shift marks a notable milestone for the retail giant, signaling its elevated status in the market. **AstraZeneca Makes Room** Meanwhile, AstraZeneca PLC (AZN) is being removed from these key indices. The pharmaceutical giant's exit isn't limited to just the primary Nasdaq-100 Index—it will also be pruned from multiple specialized indices including the Nasdaq-100 ESG Index (NDXESG), Nasdaq-100 ex Top 30 (NDX70), Nasdaq-100 ex Top 30 UCITS (NDX70U), Nasdaq-100 Sustainable ESG Select (NDXSES), Nasdaq-100 Low Volatility (NDXLV), and Nasdaq-100 Select Equal Weight (NDXSE). **What This Means for Investors** The index reconstruction takes effect prior to market open on Tuesday, January 20, 2026—the first trading day following the third Friday of the month. For portfolio managers tracking these indices, this reshuffle will trigger rebalancing activities, potentially affecting fund composition and sector exposure. Walmart's inclusion reinforces the retail sector's prominence in the benchmark, while AstraZeneca's broader removal could indicate shifting dynamics in pharmaceutical representation within Nasdaq's elite equity baskets. This index adjustment reflects the evolving landscape of large-cap equities and strategic positioning within institutional investment frameworks.
0
0
0
0